JPS62296897A - Integrated type of analysis element with multilayer structure - Google Patents
Integrated type of analysis element with multilayer structureInfo
- Publication number
- JPS62296897A JPS62296897A JP13829686A JP13829686A JPS62296897A JP S62296897 A JPS62296897 A JP S62296897A JP 13829686 A JP13829686 A JP 13829686A JP 13829686 A JP13829686 A JP 13829686A JP S62296897 A JPS62296897 A JP S62296897A
- Authority
- JP
- Japan
- Prior art keywords
- layer
- reagent
- oxidase
- hydrogen peroxide
- catalase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004458 analytical method Methods 0.000 title claims description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 34
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 102000004316 Oxidoreductases Human genes 0.000 claims abstract description 14
- 108090000854 Oxidoreductases Proteins 0.000 claims abstract description 14
- 238000011161 development Methods 0.000 claims abstract description 10
- 230000000694 effects Effects 0.000 claims description 22
- 102000016938 Catalase Human genes 0.000 claims description 21
- 108010053835 Catalase Proteins 0.000 claims description 21
- 239000003112 inhibitor Substances 0.000 claims description 14
- 238000004040 coloring Methods 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 229940123748 Catalase inhibitor Drugs 0.000 abstract description 9
- 206010018910 Haemolysis Diseases 0.000 abstract description 6
- 238000006243 chemical reaction Methods 0.000 abstract description 6
- 230000008588 hemolysis Effects 0.000 abstract description 6
- 150000002222 fluorine compounds Chemical class 0.000 abstract description 3
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 abstract description 2
- 150000001540 azides Chemical class 0.000 abstract description 2
- 238000005259 measurement Methods 0.000 abstract description 2
- 239000010410 layer Substances 0.000 description 81
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 26
- 230000007480 spreading Effects 0.000 description 13
- 238000003892 spreading Methods 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- -1 traps Substances 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 102000003992 Peroxidases Human genes 0.000 description 5
- 229910052770 Uranium Inorganic materials 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 108040007629 peroxidase activity proteins Proteins 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 239000002346 layers by function Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010089254 Cholesterol oxidase Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010055297 Sterol Esterase Proteins 0.000 description 3
- 102000000019 Sterol Esterase Human genes 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- UZSCVCWALGRUTR-UHFFFAOYSA-N 4-amino-1,5-dimethyl-2-phenylpyrazol-3-one;hydron;chloride Chemical compound Cl.CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 UZSCVCWALGRUTR-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 2
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 238000001132 ultrasonic dispersion Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- JSIAIROWMJGMQZ-UHFFFAOYSA-N 2h-triazol-4-amine Chemical class NC1=CNN=N1 JSIAIROWMJGMQZ-UHFFFAOYSA-N 0.000 description 1
- BMUDPLZKKRQECS-UHFFFAOYSA-K 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid iron(3+) hydroxide Chemical compound [OH-].[Fe+3].[N-]1C2=C(C)C(CCC(O)=O)=C1C=C([N-]1)C(CCC(O)=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 BMUDPLZKKRQECS-UHFFFAOYSA-K 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- REJHVSOVQBJEBF-OWOJBTEDSA-N 5-azaniumyl-2-[(e)-2-(4-azaniumyl-2-sulfonatophenyl)ethenyl]benzenesulfonate Chemical compound OS(=O)(=O)C1=CC(N)=CC=C1\C=C\C1=CC=C(N)C=C1S(O)(=O)=O REJHVSOVQBJEBF-OWOJBTEDSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010000659 Choline oxidase Proteins 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 description 1
- 108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108010073450 Lactate 2-monooxygenase Proteins 0.000 description 1
- 108010061951 Methemoglobin Proteins 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 108010064719 Oxyhemoglobins Proteins 0.000 description 1
- 101710132772 Peroxidase 1 Proteins 0.000 description 1
- 101710132574 Peroxidase 7 Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 108010042687 Pyruvate Oxidase Proteins 0.000 description 1
- 108010060059 Sarcosine Oxidase Proteins 0.000 description 1
- 102000008118 Sarcosine oxidase Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical compound [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 229940116901 diethyldithiocarbamate Drugs 0.000 description 1
- LMBWSYZSUOEYSN-UHFFFAOYSA-N diethyldithiocarbamic acid Chemical compound CCN(CC)C(S)=S LMBWSYZSUOEYSN-UHFFFAOYSA-N 0.000 description 1
- BADXJIPKFRBFOT-UHFFFAOYSA-N dimedone Chemical compound CC1(C)CC(=O)CC(=O)C1 BADXJIPKFRBFOT-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 229940109738 hematin Drugs 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- RSAZYXZUJROYKR-UHFFFAOYSA-N indophenol Chemical compound C1=CC(O)=CC=C1N=C1C=CC(=O)C=C1 RSAZYXZUJROYKR-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- URSKHPWQZJLJEF-UHFFFAOYSA-N iron;sulfo cyanate Chemical compound [Fe].OS(=O)(=O)OC#N URSKHPWQZJLJEF-UHFFFAOYSA-N 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920013716 polyethylene resin Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 150000004992 toluidines Chemical class 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 239000012463 white pigment Substances 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Landscapes
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
【発明の詳細な説明】
3発明の詳細な説明
〔韮業上の利用分野〕
本発明は、液体を試料とし、その甲のアナライト(分析
目標成分)?ll一定蓋するフィルム状多層分析素子に
関する。[Detailed Description of the Invention] 3. Detailed Description of the Invention [Field of Application in the Fish Industry] The present invention uses a liquid as a sample, and the first analyte (analysis target component)? This invention relates to a film-like multilayer analysis element with a fixed lid.
シート状又はフィルム状の分析素子は、分留試薬や必要
なh−作の一部?、素子中にドライの形で組込み、液体
U#+にその上に、付着させることで、簡便かつ迅速に
数体試料中のアナライト全分析することが可能である。Is the sheet-like or film-like analytical element part of the fractional distillation reagent or necessary h-product? By incorporating it in a dry form into an element and depositing liquid U#+ thereon, it is possible to easily and quickly analyze all the analytes in a sample.
これら分析素子のうち、単層のもので試薬を担持する層
の材料として、ip紙、メンブレンフィルター% k
用いるもの(特公昭36−4198号、米国%肝第56
07093号¥?)がある。Among these analytical elements, the materials for the single-layer reagent-supporting layer include IP paper and membrane filters.
What to use (Special Publication No. 36-4198, U.S. Percent Liver No. 56
No. 07093 ¥? ).
1次、単なる積層やはく離を前提とした非一体型多層分
析素子として、カラスフィルターやメンブレンフィルタ
ーを用いたり(特開昭49−11395号)、2枚の?
’、iの上に網をかけたもの(%開昭54−15109
6号、米国特許第3526480号)などが知られてい
る。As a primary, non-integral multilayer analysis element that assumes simple lamination or peeling, a glass filter or membrane filter may be used (Japanese Patent Application Laid-Open No. 11395/1983), or two filters may be used.
', shaded over i (% 1977-15109
No. 6, U.S. Pat. No. 3,526,480), etc. are known.
これら単層あるいは単なる積層型多層の分析素子は、手
足魚用として用いられているが、定量用としては十分な
信頼性を得ているとはいいかたい。These single-layer or simply laminated multi-layer analysis elements are used for limb fish, but it is difficult to say that they have achieved sufficient reliability for quantitative use.
成体不浸透性、光透過性支持体上に複数の層を配置し、
かつ谷鳩間が流体接触という暮葉で示される各層が隙間
なく接層された状態で積層された多層分析素子が、特公
昭53−21677号、特開昭55−164559号、
同55−90859号、向57−197466号、同5
7−1 [11761号、1旬57−ICM760号各
公報マ公報C開示されている。これらは、透明支持体の
片側)(、多孔性展開j曽及び機能層が多層状に配!J
′iきれはく離できない状態で一体化されている。多孔
性展開層に最外層、すなわち最上層に位置し、液体試料
が点着供給される層で、点着された敵体試料ケ展開作用
、すなわち、試料の容量にほぼ比例して液が広がる。換
言すれば、単位面槓当ジはぼ一足景の試料が分布するよ
うに、点漸供給芒れた液体試料全広ける作用?する層で
、展砥増又に計量(メータリング)層とも称せられ、こ
の層に工って展開された液体試料に、1■ちに、下j(
転)に位置する機能層に均一にCQL位面81当9はぼ
一足−biの試料が分布するように)供給さハる。Arranging multiple layers on an adult-impermeable, light-transparent support;
A multilayer analytical element in which each layer is laminated in a state where each layer is in contact with each other without any gaps, as indicated by the foliage of fluid contact, is disclosed in Japanese Patent Publication No. 53-21677, Japanese Patent Application Laid-open No. 55-164559,
No. 55-90859, No. 57-197466, No. 5
7-1 [No. 11761, No. 57-ICM760] Publications C are disclosed. These include one side of a transparent support, a porous development and a multilayered functional layer.
'iIt is integrated in a state that it cannot be peeled off. The outermost layer of the porous spreading layer, that is, the top layer, is the layer to which the liquid sample is applied. . In other words, does the unit surface spread out the entire liquid sample that has been supplied point by point, so that the sample is distributed in just one direction? This layer is also called the metering layer.
The CQL surface 81 to 9 is supplied with a sample of approximately one foot -bi uniformly distributed in the functional layer located at the top of the surface.
機能層とは、代表的には試薬層であり史e′(、反応層
、検出層、九遍へい層、元&栂層、濾過層、半透明島、
バリヤ一層、トラップ〜、吸水層、前処理層、マイグレ
ーション阻止層、ソノ他多くの線類があり、分析に必費
l試桑や機1止を受けもつものである。展開層も(幾能
鳩も一層一機能の場合と一層多機能の場合とがある。レ
リえは展開j曽が分析試薬の一部ケ営ん−Cいて、試薬
!tiを兼ねることもあジ、筐た分析拭桑の全部′に含
んでいて試薬層と反応I曽と紫兼ねる展開層であること
もある。The functional layer is typically a reagent layer;
There are barrier layers, traps, water absorption layers, pretreatment layers, migration prevention layers, and many other wires, which are responsible for the test samples and machine stops necessary for analysis. There are also cases where the development layer has a single function and cases where it has multiple functions. In some cases, it is a developing layer that is contained in the entire analysis wipe and serves as a reagent layer, a reaction layer, and a purple layer.
各層′(f″構成るための材料として、展開層に、特公
昭53−21677号公報bα載のプランシュポリマ一
層、特開昭55−164559号公報に記載の織物、編
物、特開昭57−197466号公報記載のバラバラの
穢維及び反応性菌分子材料から厄る4激維展開層、及び
特開昭55−90859号、1b−J 57−1017
60号、同57−101761号各公報に示される粒状
構造物等が一般的でおる。As materials for forming each layer'(f''), the spreading layer includes one layer of Planche polymer described in Japanese Patent Publication No. 53-21677 bα, woven fabrics and knitted fabrics described in Japanese Patent Application Publication No. 55-164559, and Japanese Patent Application Publication No. 57-1989 - 4 super-fiber development layers made from disjointed microfibers and reactive bacterial molecular materials described in Publication No. 197466, and JP-A No. 55-90859, 1b-J 57-1017
Particular structures such as those shown in Publications No. 60 and No. 57-101761 are common.
また、磯Y止層ニゼラチン、ポリアクリルアミド、ポリ
ビニルピロリドン、ポリビニルアルコール、アカロース
等の親水性高分子材料、セルロース誌導体等を挙けるこ
とが可能である。Further, hydrophilic polymer materials such as Iso Y stop layer nigeratin, polyacrylamide, polyvinylpyrrolidone, polyvinyl alcohol, acarose, cellulose conductors, etc. can be mentioned.
iJ述の多層分析素子の中で、オキシダーゼを用いて過
酸化水素全生成させ、この過酸化水素の作用に工p検卸
可訃な有色の物質全生成することのできる組成物(呈色
試薬)の組合せによって、定量ケ行うものがある。これ
らは、例えばグルコース検出に用いられるトリンダー賦
桑きして矧られる試薬組成物及びそれに類するものが卒
けられる。例えば、Ann、 Chin、 Bioch
em。In the multilayer analytical element described in iJ, oxidase is used to generate all hydrogen peroxide, and the action of this hydrogen peroxide is used to create a composition (coloring reagent) that can generate all of the detectable colored substances. ) may be used for quantitative determination. These include, for example, Trinder-containing reagent compositions used for glucose detection and the like. For example, Ann, Chin, Bioch
em.
第6巻 第24頁〜第27頁(1969年)に記載の文
献、米国特許第5992158号E!Aガd曹、特公昭
56−45599号公報等の記載が参照される。6, pp. 24-27 (1969), US Pat. No. 5,992,158 E! Reference is made to the descriptions of A Gad Cao and Japanese Patent Publication No. 56-45599.
この試薬組成物を用いた分析は浴面の影響があることが
升られでいる。これらは主として全血における赤血球中
のカタラーゼやヘムjt7パクによる過ば化水素の消費
作用等に起因することが矧られている。このような影響
全排除するための方法として、米国特許第555506
9号、同第3349006号、同第3862885号等
各明a1曹には、カタラーゼ阻害剤金、オキシダーゼを
含む試薬に首府させ、液体試料とオキシダーゼが反応時
にカタラーゼ活性を有する物質の影響を除去し、更に検
矧可能な呈色試薬1r雷む試薬と反応させることが開示
されている。It has been reported that analysis using this reagent composition is affected by the bath surface. It is believed that these are mainly caused by the consumption of hydrogen perbide by catalase in red blood cells in whole blood and heme jt7 protein. As a method to completely eliminate such effects, US Patent No. 555506
No. 9, No. 3349006, No. 3862885, etc. are based on a reagent containing catalase inhibitor gold and oxidase to remove the influence of substances that have catalase activity when the liquid sample and oxidase react. Furthermore, it is disclosed that a color-forming reagent 1r which can be inspected is reacted with a lightning reagent.
更に、′p!j開昭59−109192号公報には、多
層分析素子の展開層に近い鳩又は展開層にカタラーゼ阻
害剤を首府させることが開示されている。これは該公報
によれば、展開層素材にカタラーゼ阻害剤浴液全含浸、
乾燥させるか、又はスプレーすることで展開層中に含有
させることができることが開示されている。これらは前
記米国特許と1mJ様に浴血の影響を排除できる。Furthermore, ′p! Japanese Unexamined Patent Publication No. 59-109192 discloses that a catalase inhibitor is contained in a layer close to the developing layer of a multilayer analytical element. According to the publication, this means that the developing layer material is completely impregnated with a catalase inhibitor bath solution.
It is disclosed that it can be incorporated into the spreading layer by drying or by spraying. These can eliminate the influence of bath blood like the US patent and 1 mJ.
しかしながら、カタラーゼ阻害剤は、過酸化水素會呈色
試薬によって検知可能な呈色物質に変化する際の触媒で
あるペルオキシダーゼをも阻害することが昶られており
、呈色色素濃度全低下はせ、その結果感度を著しく低下
させる。However, catalase inhibitors are also known to inhibit peroxidase, which is the catalyst for the conversion of hydrogen peroxide into a color-forming substance that can be detected by a color-forming reagent, resulting in a total decrease in the concentration of color-forming dyes, As a result, sensitivity is significantly reduced.
これによって、分析の精度すなわち同時再現性の態化と
いう結果を引起す。This results in improved analytical precision, ie, reproducibility.
本発明の目的は、オキシダーゼにより生成する過酸化水
素の作用で検知可能な物IXX金兄る反応m酸物試薬系
全含有する多層分析素子において、浴面の影響が排除さ
れた多層分析素子を提供することにある。The object of the present invention is to provide a multilayer analytical element that eliminates the influence of the bath surface in a multilayer analytical element that contains all of the reaction m acid reagent systems that can be detected by the action of hydrogen peroxide produced by oxidase. It is about providing.
また本発明の目的は、カタラーゼ阻害剤を含有した多層
分析素子において、反射濃度低下、感度低下、ひいては
同時再現性の劣化全回避した一体型多層分析素子を提供
することにある。Another object of the present invention is to provide an integrated multilayer analytical element containing a catalase inhibitor that avoids a decrease in reflection density, a decrease in sensitivity, and a deterioration in simultaneous reproducibility.
本発明を概祝す1しば、本発明は一体型多層分V[素子
に関する発明であって、液体不浸透性でかつ光透過性の
支持体上に、少なくとも一層の試薬層及び多孔性展開層
が積層されており、かつ該試薬層の一部に、オキシダー
ゼ、及びオキシダーゼ関与の下に生成する過酸化水素を
検出するための過酸化水素検出呈色試薬組成物全含有す
る一体型多層分析素子において、カタラーゼ活性阻害剤
が、実質的に不動化された形で、かつ該過酸化水素検出
呈色試薬組成物を含有する層よpも、より該展開層に近
い側の層及び/又は該展開層に含有されていること全特
徴とする0
本発明者は、実験全型ねた結果、カタラーゼ阻害剤を、
多孔性展開層及び/又は該展開層に近い層に、実質的に
不動化された形で含有させることにニジ、前記欠点が解
消されることを見出して本発明に到達した。SUMMARY OF THE INVENTION 1 The present invention relates to an integrated multilayer device comprising at least one reagent layer and a porous layer on a liquid-impermeable and light-transparent support. An integrated multilayer analysis in which layers are laminated, and a part of the reagent layer contains oxidase and a hydrogen peroxide detection coloring reagent composition for detecting hydrogen peroxide generated under the involvement of oxidase. In the element, the catalase activity inhibitor is contained in a substantially immobilized form in a layer closer to the spreading layer than the layer containing the hydrogen peroxide detection coloring reagent composition and/or As a result of all the experiments, the present inventor discovered that the catalase inhibitor is contained in the spreading layer.
The present invention has been achieved by discovering that the above-mentioned drawbacks can be overcome by including the porous spreading layer and/or a layer close to the spreading layer in a substantially immobilized form.
本発明の多層分析素子に用いられるカタラーゼ活性阻害
剤は、公知のカタラーゼ活性全阻害するものであれば良
く、例えばシアン化合物、アジド化合物、フッ素化合物
、ギ酸及びその塩、酢酸及びその塩、アミノトリアゾー
ル類、アスコルビン酸、2価銅イオン、セミカルバジド
、ピラゾール、ジエチルジチオカルバミン酸塩、亜硝酸
塩、N−エチルマレイミド等を挙けることができる。特
に、アジド化合物、フッ素化合物、アミノトリアゾール
類、酢酸塩等は阻害効果が強く好ましい。The catalase activity inhibitor used in the multilayer analytical element of the present invention may be any known inhibitor of catalase activity, such as cyanide compounds, azide compounds, fluorine compounds, formic acid and its salts, acetic acid and its salts, aminotriazole, etc. Examples include ascorbic acid, divalent copper ion, semicarbazide, pyrazole, diethyldithiocarbamate, nitrite, N-ethylmaleimide, and the like. In particular, azide compounds, fluorine compounds, aminotriazoles, acetates, and the like are preferred because of their strong inhibitory effects.
本発明の多層分析素子は、水不浸透性でかつ光透過性め
支持体上に、過酸化水素の作用を受けて検知可能な物質
を生成する反応性組成物を含む試薬層、及び多孔性展開
層を必須の構成層として有するが、必要に応じて他の機
能を有する機能層(例えば、光反射膚、濾過層、バリヤ
一層、マイグレーション阻止層等)、若しくは構造補助
層(例えば接N層等)を有していても良いO
カタラーゼ活性阻害剤は、試薬層より表面に近い層中、
あるいは必要に応じて、これらのうち2つ以上の層中に
含有することが可能である。The multilayer analytical element of the present invention comprises a reagent layer containing a reactive composition that produces a detectable substance under the action of hydrogen peroxide, and a porous support on a water-impermeable and light-transparent support. It has a spreading layer as an essential constituent layer, but if necessary, a functional layer having other functions (for example, a light reflecting layer, a filtration layer, a barrier layer, a migration prevention layer, etc.) or a structural auxiliary layer (for example, a contact layer) may be added. etc.) The catalase activity inhibitor may be present in a layer closer to the surface than the reagent layer,
Alternatively, it can be contained in two or more of these layers, if necessary.
更にカタラーゼ活性阻害剤含有層を新たに設けることも
有効である0
特に好1しくに、多孔性展開層又はこれに隣接する層(
例えば接着層)、史に好壕しくに多孔性展開層に含有さ
せる。lfc、該阻害剤は、ペルオキシダーゼを官有す
る層に含有させるこトハ、ペルオキシダーゼの作用を阻
害し、感度低下を招くことがら好1しくない。Furthermore, it is also effective to newly provide a layer containing a catalase activity inhibitor. Particularly preferably, the porous spreading layer or the layer adjacent thereto (
(for example, an adhesive layer), it is preferably incorporated into a porous spreading layer. It is not preferable to include the lfc inhibitor in a layer containing peroxidase because it inhibits the action of peroxidase and causes a decrease in sensitivity.
本発明において、カタラーゼ活性阻害剤に、実質的に不
動化された形で所望の層に含有する必要がある。本発明
において、「実質的に不動化」とは、反応終点の時間1
で言Mされた層に十分量とど1つていることをいう。こ
れは、カタラーゼ阻害剤を含有した層全有する分析素子
と、含有しない分析素子に同一の液体試料全点着し、そ
の反射良度の差から確認することができる。In the present invention, the catalase activity inhibitor must be contained in a desired layer in a substantially immobilized form. In the present invention, "substantially immobilized" means time 1 at the end of the reaction.
This means that there is enough of it in the specified layer. This can be confirmed from the difference in reflection quality when all of the same liquid samples are deposited on an analytical element that has the entire layer containing the catalase inhibitor and an analytical element that does not contain the catalase inhibitor.
多孔性展開層に含有させるカタラーゼ活性阻害剤を実質
的に不動化する方法とじては、その多孔性展開層の素材
に応じて種々の方法が挙けられる。As a method for substantially immobilizing the catalase activity inhibitor contained in the porous spreading layer, there are various methods depending on the material of the porous spreading layer.
例えば、特開昭57−197466号公報に開示されて
いるバラバラの繊維及び反応性高分子材料の混合物から
成る繊維展開ツノにおいては、用いる繊維をi!i尚な
濃度のカタラーゼ活性阻害剤浴液に浸漬し含浸した後に
乾燥し、カタラーゼ活性阻害剤含浸繊維を作成した後、
常法に従って上記含浸繊維及び反応性高分子材料の混合
物からなる塗布液全調製し、塗布乾燥することで形成す
ることができる。For example, in a fiber expanding horn made of a mixture of loose fibers and a reactive polymeric material disclosed in Japanese Patent Application Laid-Open No. 57-197466, the fibers used are i! i After soaking and impregnating in a catalase activity inhibitor bath solution of a suitable concentration and drying to create a catalase activity inhibitor-impregnated fiber,
It can be formed by preparing a coating solution consisting of a mixture of the above-mentioned impregnated fibers and a reactive polymeric material according to a conventional method, and applying and drying the coating solution.
また、特公昭53−21677号公報に開示きれた、非
繊維質多孔性媒体層、すなわちプラッシュポリマ一層の
場合、製造工程で均一なバインダー中にカタラーゼ活性
阻害剤を分散させ次後(必些に応じて白色顔料を加え分
散させた後)、いわゆる相分離させるために貧浴ik加
え、スラリー状態として塗布することができる。In addition, in the case of a non-fibrous porous media layer, that is, a single layer of plush polymer, as disclosed in Japanese Patent Publication No. 53-21677, a catalase activity inhibitor is dispersed in a uniform binder during the manufacturing process. After adding and dispersing a white pigment (as required), a poor bath is added to cause so-called phase separation, and the coating can be applied as a slurry.
史に、特開昭55−164359号公報に開示された織
物等を用いる場合、例えば、カタラーゼ活性1訂害剤を
含浸乾燥させた後、上記カタラーゼ活性阻害剤?Il−
溶解させない溶媒に溶解したポリマー俗額に含浸乾燥さ
せ友後用いれは艮いO
オキシダーゼの関与の下に生成し7’CH2O,會、検
知可能な呈色物質に変換させるためには、ペルオキシダ
ーゼ様活性又は過酸化物活性を示す物質が必要である。In the case of using the fabric disclosed in JP-A No. 55-164359, for example, after impregnating and drying the catalase activity inhibitor, the above-mentioned catalase activity inhibitor? Il-
A polymer dissolved in a non-dissolving solvent is impregnated, dried, and then used to generate 7'CH2O, which is produced under the involvement of O oxidase, and has a peroxidase-like activity in order to convert it into a detectable color-forming substance. Alternatively, a substance exhibiting peroxide activity is required.
一般にペルオキシダーゼが用いられるが、他に合成ペル
オキシダーゼ、ヘミン、メトヘモグロビン、オキシヘモ
グロビン、ヘモグロビン、ヘモクロモーゲン、アルカリ
ヘマチン、ヘミン誘導体、スルホシアン酸鉄、タンニン
酸鉄、フェロシアン化鉄、クロム酸塩等も本発明の実施
に有用である。過酸化水素及び過酸化物質の存在で、検
知可能な変化ケ生しる呈色組成物は、任意に過当なm酸
物を用いることができる。使用しうる代表的な例として
は、必要に応じて発色剤と共に下記の物質を含むものが
挙けられる。Generally, peroxidase is used, but the present invention also uses synthetic peroxidase, hemin, methemoglobin, oxyhemoglobin, hemoglobin, hemochromogen, alkaline hematin, hemin derivatives, iron sulfocyanate, iron tannate, iron ferrocyanide, chromate, etc. useful for implementation. Color-forming compositions that exhibit a detectable change in the presence of hydrogen peroxide and peroxides may optionally employ a suitable m-acid. Typical examples that can be used include those containing the following substances along with a coloring agent if necessary.
モノアミン類、例えばアニリン及びその誘導体、ジアミ
ン類、例えば0−フェニレンジアミン、ベンジジン等、
フェノール類、例えばフェノール、チモール、クレゾー
ル、ナフトールペボリフェノール類、例えばカテコール
、グアヤコール、ビロカロール等、芳香族カルボン酸、
例えばサリチル酸、没食子酸等、ロイコ染料、flJ
t ハロイコマラカイトグリーン、米国特許第4089
747号明細書に記載されているトリアリールイミダゾ
ール類及びトリアリールメタ7 類[B、E、 パブ
(B、g、 Babb )及びり、 S、 ダニx
A/ (D、 S、 Daniel )らの名で198
4年5月21日に出願された米国特許出願第61250
9号明細書に記載されているものを含む〕、着色した染
料、例えば2,6−シクロロフエノールインドフエノー
ル、種々の生物学的物質、例エバエピネフリン、フラボ
ン酸、チロシン等、及びその他、臨床化学における当業
者に公知のもの。Monoamines such as aniline and its derivatives, diamines such as 0-phenylenediamine, benzidine, etc.
Phenols, such as phenol, thymol, cresol, naphtholpebolyphenols, such as catechol, guaiacol, virocalol, etc., aromatic carboxylic acids,
For example, salicylic acid, gallic acid, etc., leuco dye, flJ
t Halocomalachite Green, U.S. Patent No. 4089
Triarylimidazoles and triarylmetas 7 described in Specification No. 747 [B, E, Babb (B, g, Babb), S, Dani x
198 in the name of A/ (D, S, Daniel) et al.
U.S. Patent Application No. 61250, filed May 21, 2013
9], colored dyes, such as 2,6-cyclophenol indophenol, various biological substances, such as epinephrine, flavonic acid, tyrosine, etc., and others, clinical Those known to those skilled in the art of chemistry.
特に有用な呈色組成物は、前記のロイコ染料及び特に米
国特許明細書に記載さ′rしたトリアリールイミダゾー
ル官有物である。Particularly useful color-forming compositions are the leuco dyes mentioned above and the triarylimidazole compounds described in particular in the US Pat.
他の好ましい呈色m放物に、酸化可能な顔色化合物と反
応して色の変化を生じうる色形成発色剤全含むものであ
る。有用な色形成発色剤に、米国特許第4251629
号、同第4260679号及び同第4396714号各
明細曹、公報昭58−22200号公報、ヨーロッパ特
許出願第68556号明細書、英国特許第210786
3号明細書及び特公昭58−898号公報に記載されて
いるものを含めて置換アニリン類(すなわち、トルイジ
ン類)’t−fiむものである。代表的な酸化可能な顕
色化合物には、ベンジジン及びその同族体、p−フェニ
レンジアミン、p−アミンフェノール、アミノアンチピ
リン、例えば4−アミノアンチピリン等が含1れる。好
ましい顕色化合物は4−アミノアンチピリンである。Other preferred color-forming compounds include all color-forming color formers that can react with oxidizable complexion compounds to produce a color change. Useful color-forming color formers include U.S. Pat. No. 4,251,629.
No. 4260679 and No. 4396714, Publication No. 58-22200, European Patent Application No. 68556, British Patent No. 210786
Substituted anilines (i.e., toluidines) including those described in the specification of No. 3 and Japanese Patent Publication No. 58-898. Representative oxidizable color developer compounds include benzidine and its congeners, p-phenylene diamine, p-amine phenol, aminoantipyrine, such as 4-aminoantipyrine, and the like. A preferred color developing compound is 4-aminoantipyrine.
本発明に組込むことが可能なオキシダーゼ酵素としては
、グルコースオキシダーゼ、ウリカーゼ、コレステロー
ルオキシダーゼ、ザルコシンオキシダーゼ、ピルビン酸
オキシダーゼ、グリセリンオキシダーゼ、グリセロリン
酸オキシダーゼ、コリンオキシダーゼ、乳酸オキシダー
ゼ等が挙げられる。Oxidase enzymes that can be incorporated into the present invention include glucose oxidase, uricase, cholesterol oxidase, sarcosine oxidase, pyruvate oxidase, glycerin oxidase, glycerophosphate oxidase, choline oxidase, lactate oxidase, and the like.
これらオキシダーゼ酵素は、アナライトに従って選択畑
れ、また他の酵素と組合せて使用される。史に、好まし
いpH範囲及び濃度の緩衝剤と組合せて使用するのが、
当然望ましいことである。These oxidase enzymes are selected according to the analyte and used in combination with other enzymes. Historically, when used in combination with a buffer at a preferred pH range and concentration,
Of course this is desirable.
以下、本発明を実施例によジ更に具体的に説明するが、
本発明はこれら実施例に限定されるものではない。Hereinafter, the present invention will be explained in more detail with reference to Examples.
The present invention is not limited to these examples.
実施例−1
下塗り済みの厚さ180μmの透明なポリエチレンテレ
フタレート支持体上に、下記組成になるように試薬層を
塗布し乾燥した。Example 1 A reagent layer having the following composition was coated on a transparent undercoated polyethylene terephthalate support having a thickness of 180 μm and dried.
セラf 7 14.0 f
7m”1.7−シヒドロキシナフタレン
Q、835f/m”4−アミノアンチピリン・塩酸塩
1.273t/m2ベルオギシダーゼ
61500 U/m”グルコースオキシダ
ーゼ 119000 U/m”ジメドン
0.185 f/、、2
リン酸カリウム緩衝剤(pH6,1〜&2 ) 2
.8241!/m’アルカノールXC(商品名)
(121897m”からなる乾燥膜厚16μm
の試薬層
上記、試薬層上に、下記のごとく調製した塗布液を塗布
し展開層とした。Sera f 7 14.0 f
7m”1,7-hydroxynaphthalene
Q, 835f/m"4-aminoantipyrine hydrochloride
1.273t/m2 bellogysidase
61500 U/m” Glucose Oxidase 119000 U/m” Dimedone
0.185 f/,,2
Potassium phosphate buffer (pH 6,1~&2) 2
.. 8241! /m'Alkanol XC (product name)
(Dry film thickness 16μm consisting of 121897m)
Reagent layer A coating solution prepared as below was applied onto the above reagent layer to form a developing layer.
キシレン3002に、トリトン X−100(部品名)
9.75 r ’i浴溶解、史にスチレン−グリシジ
ルメタクリレート共重合体(重合比9:1)を24.5
tt入れかくはんを行い完全に俗解した後、P紙粉末
(300メツシュ以上)975ft−加え更にかくはん
金行う。Triton X-100 (part name) in xylene 3002
9.75 r'i bath, styrene-glycidyl methacrylate copolymer (polymerization ratio 9:1) was dissolved at 24.5
After thoroughly mixing and stirring, add P paper powder (more than 300 mesh) for 975ft and stir further.
更に、上記分散液中に所望量のアジ化ナトIJウム水溶
液全ゆつくり軸下する。必要に応じて超音波分散等公知
の分散法を用いて分散全行い塗布液とした。Furthermore, a desired amount of an aqueous sodium azide solution is added to the above dispersion. If necessary, a known dispersion method such as ultrasonic dispersion was used to perform all dispersion to obtain a coating solution.
上記塗布液を前記試薬層上に塗布乾燥を行い、展開N1
全作成した。The above coating liquid was applied and dried on the reagent layer, and the development N1
All created.
沢紙粉末(300メツシュ以上) 101.7
?/ m2トリドア X−1001[Ll 797
m2アジ化ナトリウム 刊己第1表に記
載の量上紀組成でかつ、乾燥膜厚300amの展開項第
1 表
更に比較分析素子として、アジ化ナトリウムが上記量に
なるようにスプレーした後、直ちに乾燥を行い比較分析
素子(2)〜(5)とした。Sawagami powder (more than 300 meshes) 101.7
? / m2 Toridor X-1001 [Ll 797
m2 Sodium azide Quantity as shown in Table 1 of Table 1. Development term for a dry film thickness of 300 am and a dry film thickness of 300 am. It was dried and used as comparative analysis elements (2) to (5).
上記本発明の分析素子(1)〜(5)及び比較分析素子
+11〜(51にグルコ−ス濃度が50.100゜50
0.500 q/az)血清′ff:1oμを谷n=1
0点着し、37℃7分間インキュベーションw行った後
546nmのフィルター上用いて反射濃度全測定した。The analytical elements (1) to (5) of the present invention and the comparative analytical elements +11 to (51 have a glucose concentration of 50.100°50
0.500 q/az) Serum 'ff: 1oμ trough n=1
After incubation at 37° C. for 7 minutes, the total reflection density was measured using a 546 nm filter.
更にグルコース濃度が100■/dtの血清にカタラー
ゼ(シグマ社)kO,1ooo、2500.5000.
7500.10000S、U / tnlになるように
離別し、同様に10μを点着し、37℃7分間インキュ
ベーションを行つfc後、546mm のフィルターを
用いて反射磯度金測定した。Furthermore, catalase (Sigma) kO, 1ooo, 2500.5000.
7500. Separated to 10000S, U/tnl, 10μ was spotted in the same way, and after fc incubation at 37°C for 7 minutes, reflection gold was measured using a 546mm filter.
結果全第2表及び第6衣に示す。All results are shown in Table 2 and No. 6.
第 2 表 グルコース濃度(my/az) so ioo 5oo so。Table 2 Glucose concentration (my/az) so iooo 5oo so.
第 6 表
カタラーゼ良度 (S、U/m/)
0 1000 2500 5000 75[1010
,0DDt31 [LaB5 CL88!l α
884 CL8B2 Q、884 0.883(4
)α8[10,889α885 G、883 α8
84 α884(5)α886 α879 α8
82 α883 Q、882 [L878(3)[
L824 α81D Q13j3 l1809
α800 CL782(41rl、803 α7
98 (L789 Q、7i 11774 0.
776(51Q、798 α794 α783 0.
771 α764 Q、766以上の結果より、本
発明の分析素子に良好な同時再現性を維持しつつ、カタ
ラーゼの影響を排除することが可能であるのに対し、比
較分析素子汀同時8現注、カタラーゼの影響のいずれか
一万又は両方に大きな問題があることが判る。Table 6 Catalase quality (S, U/m/) 0 1000 2500 5000 75 [1010
,0DDt31 [LaB5 CL88! l α
884 CL8B2 Q, 884 0.883 (4
) α8[10,889α885 G, 883 α8
84 α884 (5) α886 α879 α8
82 α883 Q, 882 [L878(3)[
L824 α81D Q13j3 l1809
α800 CL782 (41rl, 803 α7
98 (L789 Q, 7i 11774 0.
776 (51Q, 798 α794 α783 0.
771 α764 Q, 766 From the above results, it is possible to eliminate the influence of catalase while maintaining good simultaneous reproducibility with the analytical element of the present invention, whereas with the comparative analytical element It can be seen that there is a major problem with either or both of the effects of catalase.
実施例−2
下引き済み、厚さ18077mの透明なポリエチレンテ
レフタレート支持体上に、下記の組成の試薬層?!″塗
布乾燥した。Example-2 A reagent layer having the following composition was formed on a transparent polyethylene terephthalate support with a thickness of 18,077 m that had been subbed. ! “Apply and dry.
ゼラチン 15.09 t
/、、2ペルオキシダーゼ 1
220007m”4−アミノアンチピリン塩酸塩
182597m”1、y−ジヒドロキシナフタレン
α612j’/m”ジメドy
(113797m”リン酸カリウム
緩衝剤(pH6,7〜&9) 3.227 97m
”アルカノールXC(商品名) 250
Wit/m”1.2−ビス(ビニルスルホニル)エタ
ン 100 Iv/FM”から成る乾燥膜厚16μm
の試薬層。Gelatin 15.09 t
/,,2 peroxidase 1
220007m”4-aminoantipyrine hydrochloride
182597m"1,y-dihydroxynaphthalene α612j'/m"Dimedy
(113797m" Potassium phosphate buffer (pH6,7~&9) 3.227 97m
“Alkanol XC (product name) 250
Wit/m"1.2-bis(vinylsulfonyl)ethane 100 Iv/FM" dry film thickness 16 μm
reagent layer.
上記試薬層上に、下記のごとく調製し次塗布液を塗布し
展開層とした。A coating solution prepared as described below was applied onto the reagent layer to form a developing layer.
キシレン3002にトリトンX−100の1xoor2
溶解し、更にスチレン−グリシジルメタクリレート共重
合体(重合比9:1)24、5 fを溶解した。この溶
液に、下記第4表に示しfcIiのアジ化ナトリウムを
加え、公知の方法でアジ化ナトljウムを微分散した液
にf紙粉末(500メツシュ以上) 97.5 r全卵
え、更にか〈セん全行う。必要に応じて超音波分散機等
公知の方法音用いてよ記載を更に分散しても良い。史に
かくはん中に、コレステロールオキシダーゼ、コレステ
ロールエステラーゼ宮イイウシ血清アルブミン2.42
(ウシ血清アルブミン1)に対して、コレステロールオ
キシダーゼ、コレステロールエステラーゼ共ニ1000
ItJ含有)を添刀口し、かくはん?行った。1xoor2 of Triton X-100 in xylene 3002
Then, 24.5 f of styrene-glycidyl methacrylate copolymer (polymerization ratio 9:1) was dissolved. To this solution, add sodium azide of fcIi as shown in Table 4 below, and add f paper powder (500 mesh or more) to the solution in which sodium azide is finely dispersed using a known method. Or do everything. If necessary, the material may be further dispersed using a known method such as an ultrasonic dispersion machine. During stirring, cholesterol oxidase, cholesterol esterase, ox serum albumin 2.42
(bovine serum albumin 1), cholesterol oxidase, cholesterol esterase both 1000
Add ItJ containing) and stir? went.
flI租粉床(600メツシュ以上) 101
.717m”トリトンX−10013,56り/rn2
コレステロールオキシp’−セ300007m”コレス
テロールエステラーゼ 300007m”
牛血7にアルブミン 五〇
〇 ? 7m2アジ化ナトリウム
第4表に記載の倹から成る乾燥膜厚300μmの展開層
。flI flour bed (600 mesh or more) 101
.. 717m” Triton X-10013,56ri/rn2
Cholesterol oxyp'-se 300007m"Cholesterol esterase 300007m"
Bovine blood 7 and albumin 50
〇? 7m2 Sodium azide
A spread layer with a dry film thickness of 300 μm consisting of the material listed in Table 4.
第 4 衣
更に、実施例−1と同様に比較分析素子(6)に、展開
層に、アジ化ナトリウムが1.28017m”になるよ
うにスプレーを行ったものを、比較分析素子(7)とし
次。4th Clothing Furthermore, as in Example-1, the comparative analytical element (6) was sprayed with sodium azide to a spreading layer of 1.28017 m'', and this was used as the comparative analytical element (7). Next.
上記本発明の分析素子(61、(7L比較分析素子(6
)、(7)に総コレステロール層が180、′500.
450 wq/azの血清上用い、10μti点着し、
57℃7分間インキュベーションを行った後、546n
mのフィルターを用い、反射濃度を!141J定した。The analytical element of the present invention (61, (7L comparative analytical element (6)
), (7) has a total cholesterol layer of 180, '500.
Used on serum of 450 wq/az, applied 10μti,
After incubation at 57°C for 7 minutes, 546n
Reflection density using m filter! It was determined to be 141J.
反射濃度の同時再現性の測定結果全第5表に示す。更に
ヒト全血から赤血球を分離し、超音波処理を行って溶血
させ、赤血球膜全除去してヘモグロビン浴液とし、ヘモ
グロビン量が0.50.100.200.300.50
0岬/dtになるように添加上行った。ただし、この時
の総コレステロール量は180■/dtになるようにし
た。結果を第6表に示す。The measurement results of simultaneous reproducibility of reflection density are all shown in Table 5. Furthermore, red blood cells were separated from human whole blood, hemolyzed by ultrasonication, and the red blood cell membrane was completely removed to obtain a hemoglobin bath solution, and the amount of hemoglobin was 0.50.100.200.300.50.
The addition was made so that the concentration was 0 cape/dt. However, the total cholesterol amount at this time was set to be 180 μ/dt. The results are shown in Table 6.
第 5 表
(各n=10)
第 6 吹
本発明の分層r索刊6) α748 α739 α74
7 α748 Q、751 α756(7) C
L756 (1754α756 [1749Q、
76D Q、762比枚分析系子+61 Q、765
0.73 α517 [L488α4760.462
(7ン α733 α692 Q、6B7
Q、703 0.710 11709以上の結果ニジ
、本発明の分析素子はアジ化す) IJウムの冷加によ
って、反射襄匹の低下は認められず、同時再現性は良好
であった。Table 5 (n=10 each) No. 6 Split layer r index of the blowing invention 6) α748 α739 α74
7 α748 Q, 751 α756(7) C
L756 (1754α756 [1749Q,
76D Q, 762 ratio analysis system +61 Q, 765
0.73 α517 [L488α4760.462
(7n α733 α692 Q, 6B7
Q, 703 0.710 11709 or above Results (The analytical element of the present invention is azide) No decrease in reflexivity was observed due to cooling of IJ, and the simultaneous reproducibility was good.
更に、溶血に関しても、本発明の分析素子は十分安定し
た性能を示し、影響を受けていないことが明らかである
。一方比較分析素子(6)はアジ化ナトリウムが無いも
のは各コレステロール一度にわたって十分安定した同時
再現性を示しているが、溶血に対しては溶血量が増加す
るに従って、反射濃度の低下が紹められる。1次、アジ
化ナトリウム金来質的に不動化させていない比較分析素
子(6)は反射@度の大幅な低下及び同時再現性の悪化
が認められるだけでなく溶血の影響も排除しているとは
いいがたい。Furthermore, with regard to hemolysis, it is clear that the analytical element of the present invention exhibits sufficiently stable performance and is not affected by hemolysis. On the other hand, the comparative analytical element (6) without sodium azide shows sufficiently stable simultaneous reproducibility for each cholesterol once, but for hemolysis, the reflection concentration decreases as the amount of hemolysis increases. It will be done. The comparative analysis element (6), which is not immobilized due to primary sodium azide, not only shows a significant decrease in reflectance and deterioration in simultaneous reproducibility, but also eliminates the effects of hemolysis. It's hard to say.
実施例−3
下塗ジ済み、厚さ180Amの透明なポリエチレンテレ
フタレート支持体上に、下記組成の試薬)fIIIを塗
布した。Example 3 Reagent fIII having the following composition was applied onto a transparent polyethylene terephthalate support having a thickness of 180 Am and which had been prime coated.
ゼラチン(硬化) 10f/m2
ウリ77−ゼ 250
U/m”ペルオキシダーゼ 7
000U/m”pHast’tう酸塩緩衝剤
7.5 y7.zからなる膜厚FJ1
2μmの試薬層。Gelatin (hardened) 10f/m2
Uri 77-ze 250
U/m” peroxidase 7
000U/m"pHast't phosphate buffer
7.5 y7. Film thickness FJ1 consisting of z
2 μm reagent layer.
更に上記試楽層上に、下記により調製したアジ化ナトリ
ウムぽ反(よ化上用いて展開層を作成した。Further, on the above-mentioned trial layer, a developing layer was prepared using sodium azide polyethylene resin prepared as described below.
3%アジ化ナトリウム水浴gsoo−に粉末f紙(50
0メツシュ以上)を加えよくかくはんした抜水浴液?軽
く沖過し、上記粉末f紙をf別し、こtLを凍結vL燥
機を用い水分のみ全除去し、アジ化ナトリウム含没粉木
戸紙を作成した。アジ化ナトリウムの含11i100f
&J粉末f紙当りQ、120fであった。Powdered paper (50%
0 mesh or more) and stir well? It was lightly filtered, the powdered F paper was separated, and only the water content was completely removed using a freezing VL dryer to prepare powdered Kido paper impregnated with sodium azide. Containing sodium azide 11i100f
&J powder fQ per paper, 120f.
トリトンX−IC101α22/□2
上記組底でかつ、乾燥膜厚300Amの展開鳩上記尿酸
分析素子を本発明の分析素子(8)とした。TRITON
更に比較分析素子(8)及び(9)として、前者は展開
層のアジ化ナトリウムを除去したもの、後者は試薬層に
アジ化ナトリウムをα12617m2で含有させたもの
とした。Further, as comparative analytical elements (8) and (9), the former had sodium azide removed from the developing layer, and the latter had sodium azide contained in the reagent layer at α12617 m2.
上記本発明の分析素子(8)及び比較分析素子(8)及
び(9)に対して、尿酸濃度既知のヒト血清t−10μ
を添加し、37℃7分間インキュベーションし次後、6
30nmで反射濃度を測定した。結果を下記第7表に示
す。For the analytical element (8) of the present invention and comparative analytical elements (8) and (9), human serum with known uric acid concentration t-10μ
was added and incubated at 37°C for 7 minutes, then 6
Reflection density was measured at 30 nm. The results are shown in Table 7 below.
第 7 表 上段は平均値、中段は標準偏差、下段はC,V。Table 7 The upper row is the average value, the middle row is the standard deviation, and the lower row is C and V.
史に、尿ff 8 W/dtの血清に対して、カタラー
ゼ全OS、U/d 、1000 S、U/d、2500
S、U/7+7! 、 5 0 0 0
S、U/ad、 1 0 0 ロ
03−U/m/になるように添加した血清?用い同様に
6111定を行った′。結果金下記第8表に示す。Historically, catalase total OS, U/d, 1000 S, U/d, 2500
S, U/7+7! , 5 0 0 0
S, U/ad, 1 0 0 lo
Serum added to 03-U/m/? 6111 was determined in the same manner as before. The results are shown in Table 8 below.
第 8 表
以上の結果をみても、本発明の分析素子が、比較分析素
子↓りも良好なものであることが判る。Looking at the results in Table 8 and above, it can be seen that the analytical element of the present invention is better than the comparative analytical element.
以上説明し友ように、本発明の分析素子によれば、mm
の影響が排除きれると共に、感度低下ひいては同時再現
性の劣化全回避することができるという顕著な効果が奏
せられる。As explained above, according to the analytical element of the present invention, mm
This has the remarkable effect of eliminating the effects of the above, and also completely avoiding a decrease in sensitivity and, ultimately, a deterioration in simultaneous reproducibility.
Claims (1)
とも一層の試薬層及び多孔性展開層が積層されており、
かつ該試薬層の一部に、オキシダーゼ、及びオキシダー
ゼ関与の下に生成する過酸化水素を検出するための過酸
化水素検出呈色試薬組成物を含有する一体型多層分析素
子において、カタラーゼ活性阻害剤が、実質的に不動化
された形で、かつ該過酸化水素検出呈色試薬組成物を含
有する層よりも、より該展開層に近い側の層及び/又は
該展開層に含有されていることを特徴とする一体型多層
分析素子。1. At least one reagent layer and a porous development layer are laminated on a liquid-impermeable and light-transparent support,
and a part of the reagent layer contains an oxidase and a hydrogen peroxide detection coloring reagent composition for detecting hydrogen peroxide generated under the involvement of the oxidase, wherein a catalase activity inhibitor is used. is contained in a substantially immobilized form and in a layer closer to the developing layer and/or in the developing layer than the layer containing the hydrogen peroxide detection coloring reagent composition. An integrated multilayer analysis element characterized by:
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP13829686A JPS62296897A (en) | 1986-06-16 | 1986-06-16 | Integrated type of analysis element with multilayer structure |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP13829686A JPS62296897A (en) | 1986-06-16 | 1986-06-16 | Integrated type of analysis element with multilayer structure |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS62296897A true JPS62296897A (en) | 1987-12-24 |
Family
ID=15218566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP13829686A Pending JPS62296897A (en) | 1986-06-16 | 1986-06-16 | Integrated type of analysis element with multilayer structure |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS62296897A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9128084B2 (en) | 2006-10-12 | 2015-09-08 | Koninklijke Philips N.V. | Fast biosensor with reagent layer |
-
1986
- 1986-06-16 JP JP13829686A patent/JPS62296897A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9128084B2 (en) | 2006-10-12 | 2015-09-08 | Koninklijke Philips N.V. | Fast biosensor with reagent layer |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3222366C2 (en) | ||
US4781890A (en) | Multilayer chemical analytical element | |
US3983005A (en) | Integral element for the analysis of cholesterol | |
CA1192821A (en) | High glucose-determining analytical element | |
DE3213786C2 (en) | ||
US5023052A (en) | Element for analyzing body fluids | |
DE3789527T2 (en) | Dry, multilayered, analytical element. | |
US4578245A (en) | Multilayer analytical element | |
DE3785617T2 (en) | IMMUNASSAY PROCESS. | |
EP0103288B2 (en) | Multilayer analytical element | |
EP0382207B1 (en) | Analytical element for whole blood | |
CZ416197A3 (en) | Multilayer reacting testing strip | |
WO1987002267A1 (en) | Blood serum test strip | |
US4594224A (en) | Analytical element | |
US4160696A (en) | Ascorbic acid determination | |
EP0243066B1 (en) | Element and method for the determination of creatinine or creatine | |
JPH0319505B2 (en) | ||
US4166763A (en) | Analysis of lactic acid or lactate using lactate oxidase | |
DE3222707C2 (en) | ||
US5118472A (en) | Analytical element for analysis of whole blood | |
JPS62296897A (en) | Integrated type of analysis element with multilayer structure | |
JPH04636B2 (en) | ||
JPS63163164A (en) | Multi-layer analysis element | |
JP2514087B2 (en) | Total Cholesterol Analysis Factors | |
US5589347A (en) | Multilayer analysis elements for the determination of total cholesterol |